Hutchison China MediTech has won Chinese approval for a closely watched new cancer drug in a significant boost for “made in China” medicine. The medicine is the first China-discovered and developed mainstream cancer drug to win unconditional approval following a randomized clinical trial. The green light shows the country's progress in speeding up drug approvals and underlines China's emerging role in biotech, as Beijing tries to move the pharmaceutical sector up the value chain from its traditional position making cheap generic drugs.（ Boost for “made in China” medicine as Chi-Med wins key approval, CNBC）
Comment：
As self-developed drugs is highly cost, Chinese pharmaceutical companies' capability of independent innovation develops continuously due to China's in-depth implementation of the national intellectual property strategy and enhancement of IP protection. Chinese enterprises must pay attention to IP protection to gain substantial development.
（Editor Li Xingyi）
（All contents of this newspaper may not be reproduced or used without express permission）